Citations (34)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Lyne Lalonde, Manon Choinière, Élisabeth Martin, Djamal Berbiche, Sylvie Perreault & David Lussier. (2014) Costs of moderate to severe chronic pain in primary care patients – a study of the ACCORD Program. Journal of Pain Research 7, pages 389-403.
Read now
Read now
Eiichi Tanaka, Daisuke Hoshi, Ataru Igarashi, Eisuke Inoue, Kumi Shidara, Naoki Sugimoto, Eri Sato, Yohei Seto, Ayako Nakajima, Shigeki Momohara, Atsuo Taniguchi, Kiichiro Tsutani & Hisashi Yamanaka. (2013) Analysis of direct medical and nonmedical costs for care of rheumatoid arthritis patients using the large cohort database, IORRA. Modern Rheumatology 23:4, pages 742-751.
Read now
Read now
Leela Barham. (2012) Economic Burden of Chronic Pain Across Europe. Journal of Pain & Palliative Care Pharmacotherapy 26:1, pages 70-72.
Read now
Read now
Rikke Søgaard, Jan Sørensen, Louise Linde & Merete L Hetland. (2010) The significance of presenteeism for the value of lost production: the case of rheumatoid arthritis. ClinicoEconomics and Outcomes Research 2, pages 105-112.
Read now
Read now
Stuart Silverman, Ellen M. Dukes, Stephen S. Johnston, Nancy A. Brandenburg, Alesia Sadosky & Dan M. Huse. (2009) The economic burden of fibromyalgia: comparative analysis with rheumatoid arthritis. Current Medical Research and Opinion 25:4, pages 829-840.
Read now
Read now
G Kobelt, P Lindgren & P Geborek. (2009) Costs and outcomes for patients with rheumatoid arthritis treated with biological drugs in Sweden: a model based on registry data. Scandinavian Journal of Rheumatology 38:6, pages 409-418.
Read now
Read now
K. Puolakka, H. Kautiainen, T. Möttönen, P. Hannonen, M. Korpela, M. Hakala, R. Luukkainen, K. Vuori, H. Blåfield, M. Leirisalo‐Repo & for the FIN‐RACo Trial Group. (2009) Use of the Stanford Health Assessment Questionnaire in estimation of long‐term productivity costs in patients with recent‐onset rheumatoid arthritis. Scandinavian Journal of Rheumatology 38:2, pages 96-103.
Read now
Read now
J. L. Hoving, G. M. Bartelds, J. K. Sluiter, K. Sadiraj, I. Groot, W. F. Lems, B. A. C. Dijkmans, C. A. Wijbrandts, P. P. Tak, M. T. Nurmohamed, A. E. Voskuyl & M. H. W. Frings‐Dresen. (2009) Perceived work ability, quality of life, and fatigue in patients with rheumatoid arthritis after a 6‐month course of TNF inhibitors: prospective intervention study and partial economic evaluation. Scandinavian Journal of Rheumatology 38:4, pages 246-250.
Read now
Read now
Chenglong Han, Ning Zhao, Abizer Gaslightwala & Mohan Bala. (2007) An epidemiological and healthcare utilisation study of rheumatoid arthritis in an adult population in the US. Journal of Medical Economics 10:4, pages 489-499.
Read now
Read now
Articles from other publishers (25)
Elahe Hatami, Mobina Aghajani, Makan Pourmasoumi, Farahnaz Haeri, Behnoosh Boozari, Saeed Nezamoleslami, Cain C. T. Clark, Shokufeh Nezamoleslami & Reza Ghiasvand. (2022) The relationship between animal flesh foods consumption and rheumatoid arthritis: a case-control study. Nutrition Journal 21:1.
Crossref
Crossref
Johan Dalén, Anushri Chitkara, Axel Svedbom, Tor Olofsson, Amy Puenpatom, Christopher M. Black & Zaina P. Qureshi. (2021) Health-Care and Societal Costs Associated with Non-Persistence with Subcutaneous TNF-α Inhibitors in the Treatment of Inflammatory Arthritis (IA): A Retrospective Observational Study. Advances in Therapy 39:6, pages 2468-2486.
Crossref
Crossref
Nadia M T Roodenrijs, Paco M J Welsing, Marlies C van der Goes, Janneke Tekstra, Floris P J G Lafeber, Johannes W G Jacobs & Jacob M van Laar. (2021) Healthcare utilization and economic burden of difficult-to-treat rheumatoid arthritis: a cost-of-illness study. Rheumatology 60:10, pages 4681-4690.
Crossref
Crossref
Ping-Hsuan Hsieh, Olivia Wu, Claudia Geue, Emma McIntosh, Iain B McInnes & Stefan Siebert. (2020) Economic burden of rheumatoid arthritis: a systematic review of literature in biologic era. Annals of the Rheumatic Diseases 79:6, pages 771-777.
Crossref
Crossref
Johan K. Wallman, Jonas K. Eriksson, Jan-Åke Nilsson, Tor Olofsson, Lars-Erik Kristensen, Martin Neovius & Pierre Geborek. (2016) Costs in Relation to Disability, Disease Activity, and Health-related Quality of Life in Rheumatoid Arthritis: Observational Data from Southern Sweden. The Journal of Rheumatology 43:7, pages 1292-1299.
Crossref
Crossref
Jonas K Eriksson, Johan A Karlsson, Johan Bratt, Ingemar F Petersson, Ronald F van Vollenhoven, Sofia Ernestam, Pierre Geborek & Martin Neovius. (2015) Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial. Annals of the Rheumatic Diseases 74:6, pages 1094-1101.
Crossref
Crossref
Jonas K Eriksson, Kari Johansson, Johan Askling & Martin Neovius. (2015) Costs for hospital care, drugs and lost work days in incident and prevalent rheumatoid arthritis: how large, and how are they distributed?. Annals of the Rheumatic Diseases 74:4, pages 648-654.
Crossref
Crossref
Cheryl Barnabe, Nguyen Xuan Thanh, Arto Ohinmaa, Joanne Homik, Susan G. Barr, Liam Martin & Walter P. Maksymowych. (2014) Effect of Remission Definition on Healthcare Cost Savings Estimates for Patients with Rheumatoid Arthritis Treated with Biologic Therapies. The Journal of Rheumatology 41:8, pages 1600-1606.
Crossref
Crossref
Gisela Kobelt. (2014) Treating to Target with Etanercept in Rheumatoid Arthritis: Cost-Effectiveness of Dose Reductions When Remission Is Achieved. Value in Health 17:5, pages 537-544.
Crossref
Crossref
Eleanor M. Heather, Katherine Payne, Mark Harrison & Deborah P. M. Symmons. (2013) Including Adverse Drug Events in Economic Evaluations of Anti-Tumour Necrosis Factor-α Drugs for Adult Rheumatoid Arthritis: A Systematic Review of Economic Decision Analytic Models. PharmacoEconomics 32:2, pages 109-134.
Crossref
Crossref
A. Kalkan, E. Hallert, L. Bernfort, M. Husberg & P. Carlsson. (2013) Costs of rheumatoid arthritis during the period 1990-2010: a register-based cost-of-illness study in Sweden. Rheumatology 53:1, pages 153-160.
Crossref
Crossref
Jolanta Grygielska. (2013) The impact of rheumatoid arthritis on the economic situation of Polish households. Rheumatology 51:5, pages 348-354.
Crossref
Crossref
Aniket A. Kawatkar, Steven J. Jacobsen, Gerald D. Levy, Swati S. Medhekar, Kumarapuram V. Venkatasubramaniam & Lisa J. Herrinton. (2012) Direct medical expenditure associated with rheumatoid arthritis in a nationally representative sample from the medical expenditure panel survey. Arthritis Care & Research 64:11, pages 1649-1656.
Crossref
Crossref
Jeong-Mi Kwon, Soo-Kyung Cho, Jin-Hee Kim & Eui-Kyung Lee. (2011) Medical costs for Korean patients with rheumatoid arthritis based on the national claims database. Rheumatology International 32:9, pages 2893-2899.
Crossref
Crossref
Ilker Kemal Yucel, Emire Seyahi, Ozgur Kasapcopur & Nil Arisoy. (2011) Economic impact of juvenile idiopathic arthritis and familial Mediterranean fever. Rheumatology International 32:7, pages 1955-1962.
Crossref
Crossref
Julie Harker, Kim J. Reid, Geertruida E. Bekkering, Eliane Kellen, Malgorzata M. Bala, Rob Riemsma, Gill Worthy, Kate Misso & Jos Kleijnen. (2012) Epidemiology of Chronic Pain in Denmark and Sweden. Pain Research and Treatment 2012, pages 1-30.
Crossref
Crossref
Maurizio Benucci, Gianantonio Saviola, Paola Baiardi & Mariangela Manfredi. (2010) Cost-effectiveness treatment with Rituximab in patients with rheumatoid arthritis in real life. Rheumatology International 31:11, pages 1465-1469.
Crossref
Crossref
Gisela Kobelt, Ingrid Lekander, Andrea Lang, Bernd Raffeiner, Costantino Botsios & Pierre Geborek. (2011) Cost-effectiveness of etanercept treatment in early active rheumatoid arthritis followed by dose adjustment. International Journal of Technology Assessment in Health Care 27:3, pages 193-200.
Crossref
Crossref
Carlo A. Marra, Nick Bansback, Aslam H. Anis & Kamran Shojania. (2011) Introduction to economic modeling for clinical rheumatologists: application to biologic agents in rheumatoid arthritis. Clinical Rheumatology 30:S1, pages 9-18.
Crossref
Crossref
Ingrid Lekander, Fredrik Borgström, Patrick Svarvar, Tryggve Ljung, Cheryl Carli & Ronald F. van Vollenhoven. (2010) Cost-effectiveness of real-world infliximab use in patients with rheumatoid arthritis in Sweden. International Journal of Technology Assessment in Health Care 26:1, pages 54-61.
Crossref
Crossref
M. Osiri & A. Maetzel. 2010. Handbook of Disease Burdens and Quality of Life Measures. Handbook of Disease Burdens and Quality of Life Measures
1733
1750
.
Peter Lindgren, Pierre Geborek & Gisela Kobelt. (2009) Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden. International Journal of Technology Assessment in Health Care 25:02, pages 181-189.
Crossref
Crossref
Slobodan Janković, Marina Kostić, Marija Radosavljević & Snežana Jovanović. (2009) Costs of Rheumatoid Arthritis in a Balkan Country (Serbia). East European Politics and Societies: and Cultures 23:1, pages 135-138.
Crossref
Crossref
Saralynn Allaire, Frederick Wolfe, Jingbo Niu, Yuqing Zhang, Bin Zhang & Michael LaValley. (2008) Evaluation of the effect of anti-tumor necrosis factor agent use on rheumatoid arthritis work disability: The jury is still out. Arthritis & Rheumatism 59:8, pages 1082-1089.
Crossref
Crossref
J. Lundkvist, F. Kastäng & G. Kobelt. (2007) The burden of rheumatoid arthritis and access to treatment: health burden and costs. The European Journal of Health Economics 8:S2, pages 49-60.
Crossref
Crossref